Medication for Opioid Relapse Prevention: What Are the Options?
DeBinge opioid transition: When travelling to DeBinge in The Bahamas for OLANI treatment, there is no requirement to complete a separate opioid-free waiting window before arrival. DeBinge uses a medically supervised 4-to-5-day buprenorphine transition. Buprenorphine is introduced to bridge the patient away from full-agonist opioids, stabilised and tapered over the first several days, and the O’Neil Long-Acting Naltrexone Implant is typically inserted around day 4 or 5 while buprenorphine is still being tapered. The planned overlap continues as buprenorphine clears and the implant gradually releases naltrexone. This pathway is clinician-supervised because mistimed naltrexone exposure can precipitate withdrawal.
Based on DeBinge’s clinical experience in The Bahamas since 2018, the implant typically provides its strongest craving and relapse-prevention support on average 9 months, while clinically meaningful opioid-receptor blockade may persist for longer, in some patients up to about 15 months. This longer blockade may continue to reduce opioid effects and overdose risk.
Ongoing recovery: The implant is not a cure. The DeBinge programme includes a full year of professional counselling after implantation to address the behavioural and psychological side of addiction.
Medication can be an important part of preventing a return to opioid use after detox, rehab or another period of recovery. But the medications used for opioid use disorder do not all work in the same way, and no single option is automatically right for every patient.
The three medications approved by the U.S. Food and Drug Administration for opioid use disorder are buprenorphine, methadone and naltrexone. Buprenorphine and methadone act on opioid receptors and can reduce withdrawal and cravings. Naltrexone works differently as an opioid antagonist, blocking opioid receptors and reducing or preventing opioid effects while adequate medication levels are present.
Medication is usually most useful as part of a broader treatment plan that may also include counselling, mental-health treatment, relapse-prevention planning, naloxone, social support and continuing clinical follow-up.
Related: If naltrexone is the preferred relapse-prevention medication, the next question is often how to get onto it safely. Read our guide to the medically managed transition from opioids to naltrexone.
Prepared for Medical Review
Dr Fergus Law, BSc, MBChB, FRCPsych
Consultant Psychiatrist specialising in substance misuse and addiction psychiatry.
This article has been prepared as an evidence-informed educational resource and is awaiting formal clinical approval. Until formal review has been completed, it should not be represented as medically reviewed.
View Dr Fergus Law’s professional profile
Why Medication Can Matter After Opioid Detox or Rehab
Finishing detox does not necessarily mean opioid use disorder has been fully treated.
Cravings, conditioned triggers, stress, pain, mental-health symptoms and access to opioids can remain after withdrawal has ended.
CDC states that medication treatment for opioid use disorder is associated with reduced overdose risk and overall mortality. CDC also advises that detoxification by itself, without medication treatment for OUD, is not recommended because of increased risks of resuming opioid use, overdose and overdose death.
People often search for a “medication to prevent opioid relapse.” Clinically, these medications are treatments for opioid use disorder. Their role is broader than simply preventing one episode of relapse.
In This Guide
- The three main medication options
- Buprenorphine vs methadone vs naltrexone
- How buprenorphine works
- How methadone works
- How naltrexone works
- When medications can be started
- Which medications help cravings?
- Why adherence matters
- Long-acting medication options
- How treatment choice is made
- Medication and counselling
- Medication and overdose prevention
- Frequently asked questions
- Clinical sources
Three Medication Approaches Are Used to Treat Opioid Use Disorder
FDA-approved medications for opioid use disorder use three different pharmacological approaches.
Buprenorphine
Buprenorphine partially activates mu-opioid receptors. It can suppress withdrawal, reduce opioid cravings and blunt the effects of other opioids.
Methadone
Methadone activates mu-opioid receptors and can reduce withdrawal and cravings while stabilising opioid receptor activity.
Naltrexone
Naltrexone blocks opioid receptors rather than activating them. It can prevent or substantially reduce the expected euphoric and sedative effects of opioids.
Their pharmacology, initiation requirements, treatment settings and adherence challenges differ.
Buprenorphine vs Methadone vs Naltrexone
| Feature | Buprenorphine | Methadone | Naltrexone |
|---|---|---|---|
| Medication type | Partial mu-opioid receptor agonist | Full mu-opioid receptor agonist | Opioid receptor antagonist |
| Reduces withdrawal | Yes | Yes | Not used to treat active opioid withdrawal |
| Craving effect | Can reduce opioid cravings | Can reduce opioid cravings | Can reduce cravings for some patients, while its primary action is opioid receptor blockade |
| Blocks or blunts other opioids | Can blunt effects | Can blunt effects when appropriately dosed | Designed to block opioid effects |
| Opioid-free period first? | Usually initiated when withdrawal has begun to avoid precipitated withdrawal in physically dependent patients | No prolonged opioid-free period is required in the same way as naltrexone | Yes, an appropriate opioid-free period is required |
| Physical opioid dependence during treatment | Can occur | Can occur | No opioid physical dependence caused by naltrexone itself |
| U.S. treatment access | Can be prescribed by appropriately registered clinicians | For OUD, generally dispensed through SAMHSA-certified opioid treatment programs | Can be prescribed and administered by licensed prescribers |
| FDA-approved long-acting forms | Extended-release injectable formulations are available | OUD treatment generally uses oral methadone through opioid treatment programs | Extended-release monthly injectable naltrexone is FDA-approved for OUD |
Treatment should be matched to the individual after clinical assessment.
Buprenorphine for Opioid Use Disorder
Buprenorphine is a partial mu-opioid receptor agonist.
It activates opioid receptors less fully than a full agonist such as methadone, while still being able to suppress withdrawal symptoms and reduce opioid cravings.
CDC states that buprenorphine can suppress and reduce opioid cravings and blunt or block the effects of opioids.
How Is Buprenorphine Given?
FDA-approved buprenorphine products for OUD include sublingual or buccal formulations and extended-release injections.
Some products combine buprenorphine with naloxone.
Starting Buprenorphine
Timing matters when buprenorphine is started in someone who remains physically dependent on full-agonist opioids.
Traditional initiation commonly occurs after signs of opioid withdrawal have developed because starting buprenorphine too early can precipitate withdrawal.
The appropriate strategy may differ according to the opioid involved, including fentanyl exposure, previous treatment and the patient’s clinical condition.
Methadone for Opioid Use Disorder
Methadone is a long-acting full mu-opioid receptor agonist.
When used appropriately for OUD treatment, it can reduce opioid withdrawal and cravings and support physiological stability.
Methadone has a long history of use in opioid-use-disorder treatment.
How Is Methadone Accessed in the United States?
In the United States, methadone used specifically to treat opioid use disorder is generally dispensed through federally regulated, SAMHSA-certified opioid treatment programs.
Does Methadone Simply Replace One Opioid With Another?
This description oversimplifies treatment.
Methadone is prescribed in a controlled therapeutic framework with the aim of stabilising opioid receptor activity, suppressing withdrawal, reducing cravings and reducing harmful patterns of illicit opioid use.
Naltrexone for Opioid Relapse Prevention
Naltrexone works very differently from buprenorphine and methadone.
It is an opioid receptor antagonist, meaning it binds to opioid receptors without activating them.
While sufficient medication levels are present, naltrexone can block or substantially reduce the euphoric and sedating effects expected from opioids.
Why Is Naltrexone Used After Detox?
Because naltrexone is an antagonist, the patient must first complete an appropriate opioid-free period.
SAMHSA currently advises waiting at least seven days after the last use of short-acting opioids and approximately 10 to 14 days after long-acting opioids before initiating naltrexone, although individual clinical assessment remains necessary.
Does Naltrexone Stop Cravings?
SAMHSA describes naltrexone as being able to reduce or suppress opioid cravings, but individual responses vary.
Its defining pharmacological action remains opioid receptor blockade.
Naltrexone should therefore not be presented as guaranteeing that cravings disappear.
FDA-Approved Naltrexone for OUD
In the United States, extended-release injectable naltrexone is FDA-approved for opioid use disorder.
Oral naltrexone can block opioid receptors, but the oral formulation is not FDA-approved as the OUD treatment formulation described by SAMHSA for this indication.
When Can Medication Be Started After Opioid Use?
One major difference between the three medication strategies is how treatment begins.
Withdrawal Timing Matters
Traditional initiation typically requires signs of opioid withdrawal before the first dose to reduce the risk of precipitated withdrawal.
Can Be Initiated Without Detox First
Methadone treatment does not require completion of an opioid-free detoxification period in the same way antagonist treatment does.
Requires Opioid-Free Preparation
Significant opioid dependence must have resolved before naltrexone is started to avoid precipitated withdrawal.
Which Medication Helps With Opioid Cravings?
Cravings are one reason medication treatment may be important after detox or rehab.
| Medication | Relationship to Opioid Cravings |
|---|---|
| Buprenorphine | CDC describes buprenorphine as suppressing and reducing opioid cravings as well as withdrawal. |
| Methadone | CDC describes methadone as reducing opioid cravings and withdrawal. |
| Naltrexone | SAMHSA states that naltrexone can reduce or suppress opioid cravings, although its primary distinguishing action is opioid receptor blockade. |
Medication is not the only tool for cravings. Environmental changes, counselling, pain management, mental-health treatment and a prepared craving-response plan may also be important.
Why Does Medication Adherence Matter?
A medication can only provide its intended pharmacological effect while treatment is being received appropriately.
Missed doses, stopping treatment or long gaps in care can change the protection provided by medication.
Adherence is therefore an important part of selecting a treatment strategy.
- Can the patient reliably take medication as prescribed?
- Can the patient attend required treatment appointments?
- Is transportation available?
- Has daily medication adherence been difficult before?
- Would a longer-acting formulation reduce repeated medication decisions?
- What happens if an appointment or dose is missed?
Treatment burden, access, work, transport, housing, mental health and medication format can all affect adherence.
What Long-Acting Medication Options Exist?
Longer-acting medications can reduce the number of times a patient needs to make a medication-taking decision.
Extended-Release Buprenorphine
FDA-approved extended-release injectable buprenorphine products can provide prolonged medication delivery without daily dosing.
Extended-Release Injectable Naltrexone
FDA-approved extended-release naltrexone for OUD is administered as an intramuscular injection approximately once every four weeks.
Implant-Based Naltrexone
Naltrexone implants are used in some jurisdictions outside the United States to provide longer antagonist exposure.
Clinical Follow-Up Still Matters
Longer medication duration does not eliminate the need for monitoring, counselling, recovery planning and reassessment.
Long-Acting Naltrexone at DeBinge
DeBinge provides treatment in Nassau, The Bahamas. For appropriately assessed patients, treatment may include a long-acting naltrexone implant alongside counselling and continuing recovery planning.
The rationale for a longer-acting formulation is partly adherence-related: instead of depending on repeated daily medication decisions, antagonist treatment can continue for a substantially longer period.
That does not mean the implant should be considered a replacement for counselling, mental-health treatment or a wider relapse-prevention strategy.
Suitability, detox status and timing must be assessed clinically before antagonist treatment is initiated.
Learn more: Long-Acting Naltrexone Implant .
How Is the Right Opioid Treatment Medication Chosen?
Medication selection should be individualised.
Factors that may influence the decision include:
Current Opioid Use
Whether the person is actively using opioids, withdrawing or already opioid-free can affect which medications can be initiated immediately.
Previous Treatment
Previous experience with buprenorphine, methadone, naltrexone, detox or rehab may provide useful information.
Cravings and Withdrawal
The current severity of withdrawal and opioid cravings may influence treatment planning.
Adherence
Difficulty taking daily medication or attending frequent treatment may make formulation and treatment setting important.
Medical History
Other medical conditions, medications and individual safety considerations must be reviewed.
Patient Preference
Treatment is more likely to be sustainable when the patient understands the options and participates in the decision.
Treatment Access
Local availability, prescribing rules, transportation and cost can affect which treatment can realistically be maintained.
Recovery Goals
The patient’s treatment goals and preferences regarding agonist, partial agonist or antagonist treatment should be discussed.
It is “Which evidence-based treatment is appropriate, accessible and sustainable for this individual?”
Does Medication Replace Counselling or Relapse-Prevention Planning?
Medication can treat important biological and behavioural aspects of opioid use disorder, but recovery may also involve problems that medication alone does not resolve.
These can include:
- relationship problems;
- trauma;
- depression or anxiety;
- housing instability;
- pain;
- high-risk social networks;
- work or financial stress;
- learned opioid-use triggers;
- family conflict;
- lack of daily structure.
SAMHSA’s TIP 63 describes medication together with individualized medical, psychosocial and recovery services that may support people with OUD.
Read: Medically Supervised Relapse Prevention: What Happens After Detox or Rehab?
Naloxone and Overdose Prevention Still Matter
Medication treatment does not mean overdose planning becomes unnecessary.
Naloxone should remain available where opioid exposure is possible.
This is especially important after detox, rehab or other periods of reduced opioid exposure because opioid tolerance may have fallen.
Administer naloxone if available, contact emergency services immediately and remain with the person until professional help arrives.
Read: Opioid Tolerance After Detox: Why Overdose Risk Can Increase .
Do Not Try to Overcome Naltrexone Blockade With Larger Opioid Amounts
Naltrexone reduces or blocks opioid effects while adequate antagonist levels are present.
Attempting to overcome that blockade by taking increasingly large opioid quantities can be dangerous.
Opioid sensitivity can also increase after a period of reduced opioid exposure, meaning overdose vulnerability may increase when antagonist effects decline or treatment ends.
Medication Planning Should Ideally Begin Before Detox or Rehab Ends
One avoidable problem is waiting until someone has returned home before deciding what ongoing OUD treatment will look like.
Assess the opioid-use pattern
Identify the opioids involved, recent exposure, withdrawal status and previous treatment.
Discuss all evidence-based medication options
Buprenorphine, methadone and naltrexone have different benefits, limitations and initiation requirements.
Choose the treatment pathway
Medication choice should reflect clinical suitability, access and patient preference.
Arrange follow-up before discharge
Avoid unnecessary gaps between structured treatment and ongoing medication care.
Prepare a craving and relapse plan
Medication should sit inside a wider plan for triggers, cravings and sudden increases in risk.
Provide overdose protection
Include naloxone and overdose-response education wherever future opioid exposure remains possible.
Build the Full Opioid Relapse-Prevention Plan
Medication can be a major part of treatment, but relapse prevention can also involve cravings, triggers, counselling, mental health, family support, daily structure, overdose prevention and rapid response when risk increases.
Discuss Whether Long-Acting Naltrexone May Be Appropriate
DeBinge provides addiction treatment in Nassau, The Bahamas. For appropriately assessed patients, treatment may include long-acting implant-based naltrexone alongside counselling and continuing recovery support.
Treatment suitability depends on current opioid exposure, completion of an appropriate opioid-free period, previous treatment, medical history, medications and individual recovery goals.
DeBinge does not operate a treatment facility in the United States, and naltrexone implant formulations are not FDA-approved for routine clinical use in the United States.
Medication for Opioid Relapse Prevention: FAQs
What medications are used to help prevent opioid relapse?
FDA-approved medications for opioid use disorder include buprenorphine, methadone and naltrexone. They work differently and treatment should be selected according to individual clinical circumstances.
Which medication is best for opioid relapse prevention?
There is no single medication that is best for every patient. The appropriate option depends on current opioid use, withdrawal status, previous treatment, medical history, treatment access, adherence considerations and patient preference.
Does buprenorphine reduce opioid cravings?
Yes. CDC states that buprenorphine can suppress and reduce opioid cravings as well as withdrawal symptoms.
Does methadone reduce opioid cravings?
Yes. Methadone can reduce opioid cravings and withdrawal and is an established treatment for opioid use disorder.
How does naltrexone work for opioid addiction?
Naltrexone is an opioid receptor antagonist. It blocks opioid receptors and can prevent or substantially reduce expected opioid effects while adequate medication levels are present.
Does naltrexone stop opioid cravings?
SAMHSA states that naltrexone can reduce or suppress cravings, but individual responses vary. Its primary distinguishing action is opioid receptor blockade, so it should not be presented as guaranteeing that cravings disappear.
Can naltrexone be started immediately after opioid use?
No. An appropriate opioid-free period is required before naltrexone is started. Beginning antagonist treatment while significant opioid physical dependence remains can precipitate withdrawal.
Can buprenorphine be started immediately after opioid use?
Timing depends on the clinical situation. Traditional buprenorphine initiation generally begins once withdrawal is present to reduce the risk of precipitated withdrawal. A clinician should determine the appropriate initiation strategy.
Do patients need to detox completely before starting methadone?
Methadone treatment for opioid use disorder does not require completion of a prolonged opioid-free period in the way naltrexone treatment does. Initiation and dose adjustment require appropriate clinical supervision.
Can medication for opioid use disorder be used long term?
Yes. Treatment duration should be individualized. SAMHSA notes that medications for OUD can be used safely for extended periods, and treatment should not be stopped solely because an arbitrary amount of time has passed.
Does medication replace counselling?
Medication treats important aspects of opioid use disorder, while counselling and other supports may address triggers, mental health, relationships, coping and recovery needs. The appropriate combination depends on the individual.
Are naltrexone implants FDA-approved in the United States?
No. Naltrexone implant formulations are not FDA-approved for routine clinical use in the United States. Extended-release injectable naltrexone is an FDA-approved formulation for opioid use disorder.
Should someone still have naloxone while receiving OUD medication?
Where opioid exposure remains possible, naloxone and overdose-response education should remain part of the safety plan.
Evidence Used in This Guide
FDA — Medications for Opioid Use Disorder
Current FDA information on buprenorphine, methadone and naltrexone as approved treatments for opioid use disorder.
CDC — Opioid Use Disorder: Treating
CDC clinical guidance covering buprenorphine, methadone and naltrexone, medication treatment, cravings and risks associated with detoxification alone.
SAMHSA — Medications for Substance Use Disorders
SAMHSA information describing buprenorphine, methadone and naltrexone as evidence-based medication treatments for opioid use disorder.
SAMHSA — Naltrexone
Current SAMHSA information on opioid receptor blockade, opioid-free preparation, cravings and extended-release injectable naltrexone.
SAMHSA — TIP 63: Medications for Opioid Use Disorder
SAMHSA’s Treatment Improvement Protocol covering methadone, buprenorphine, naltrexone and additional recovery services for opioid use disorder.
CDC — Treatment of Substance Use Disorders
CDC information on medication for opioid use disorder, treatment retention and reduction of opioid-related overdose risk.
Medication approvals, treatment regulations and clinical guidance can change. Individual treatment decisions should be made with appropriately qualified healthcare professionals.
Related: If naltrexone is the preferred relapse-prevention medication, the next question is often how to get onto it safely. Read our guide to the medically managed transition from opioids to naltrexone.
Prepared for Medical Review
Dr Fergus Law, BSc, MBChB, FRCPsych
Consultant Psychiatrist specialising in substance misuse and addiction psychiatry.
This article has been prepared as an educational resource concerning medications for opioid use disorder, opioid relapse prevention, medication adherence and continuing recovery treatment. It is awaiting formal clinical approval.
View Dr Fergus Law’s professional profile
This Article Does Not Recommend One Medication for an Individual
This page provides general educational information. It does not diagnose opioid use disorder, determine treatment suitability or recommend buprenorphine, methadone, naltrexone or another treatment for a specific person.
Do not abruptly stop methadone, buprenorphine, prescribed opioids or another prescribed medication based on this article.
Naltrexone requires appropriate opioid-free preparation before initiation. Starting naltrexone while significant opioid physical dependence remains can precipitate withdrawal.
Buprenorphine initiation also requires appropriate clinical timing because starting it too early in some opioid-dependent patients can precipitate withdrawal.
If someone cannot be awakened, has very slow or stopped breathing, or opioid overdose is suspected, administer naloxone if available and contact local emergency services immediately.
DeBinge is located in Nassau, The Bahamas. We do not operate a treatment facility in the United States. Naltrexone implant formulations are not FDA-approved for routine clinical use in the United States.